Multiple Sclerosis And Related Disorders SCIE

国际简称：MULT SCLER RELAT DIS 参考译名：多发性硬化症及相关疾病

主要研究方向：CLINICAL NEUROLOGY 非预警期刊审稿周期：

《多发性硬化症及相关疾病》(Multiple Sclerosis And Related Disorders)是一本由Elsevier出版的以CLINICAL NEUROLOGY为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。

3区中科院分区
Q2 JCR分区
474 年发文量
2.9 IF影响因子
未开放 是否OA
25 H-index
2012 创刊年份
6 issues/year 出版周期
English 出版语言

Multiple Sclerosis is an area of ever expanding research and escalating publications. Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the central nervous system. The primary aim of this new journal is the rapid publication of high quality original research in the field. Important secondary aims will be timely updates and editorials on important scientific and clinical care advances, controversies in the field, and invited opinion articles from current thought leaders on topical issues. One section of the journal will focus on teaching, written to enhance the practice of community and academic neurologists involved in the care of MS patients. Summaries of key articles written for a lay audience will be provided as an on-line resource.

A team of four chief editors is supported by leading section editors who will commission and appraise original and review articles concerning: clinical neurology, neuroimaging, neuropathology, neuroepidemiology, therapeutics, genetics / transcriptomics, experimental models, neuroimmunology, biomarkers, neuropsychology, neurorehabilitation, measurement scales, teaching, neuroethics and lay communication.

[ 查看全部 ]

投稿咨询加急咨询

投稿热线：400-888-7501

Multiple Sclerosis And Related Disorders期刊信息

ISSN：2211-0348
出版语言：English
是否OA：未开放
E-ISSN：2211-0356
出版地区：ENGLAND
是否预警：否
出版商：Elsevier
出版周期：6 issues/year
创刊时间：2012
开源占比：0.135
Gold OA文章占比：19.66%
OA被引用占比：0.0983...
出版国人文章占比：0.05
出版撤稿占比：0.0019...
研究类文章占比：86.71%

Multiple Sclerosis And Related Disorders CiteScore评价数据（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指数

5.8

0.99

0.8

学科类别	分区	排名	百分位
大类：Medicine 小类：Neurology (clinical)	Q2	121 / 400	69%
大类：Medicine 小类：Neurology	Q2	59 / 192	69%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Multiple Sclerosis And Related Disorders中科院评价数据

中科院 2023年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	CLINICAL NEUROLOGY 临床神经病学	4区

中科院 2022年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	CLINICAL NEUROLOGY 临床神经病学	4区

中科院 2021年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	CLINICAL NEUROLOGY 临床神经病学	4区

中科院 2021年12月基础版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	CLINICAL NEUROLOGY 临床神经病学	3区

中科院 2021年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	CLINICAL NEUROLOGY 临床神经病学	4区

中科院 2020年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	CLINICAL NEUROLOGY 临床神经病学	4区

Multiple Sclerosis And Related Disorders JCR评价数据（2023-2024年最新版）

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：CLINICAL NEUROLOGY	SCIE	Q2	99 / 277	64.4%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：CLINICAL NEUROLOGY	SCIE	Q2	82 / 278	70.68%

Multiple Sclerosis And Related Disorders历年数据统计

影响因子

中科院分区

Multiple Sclerosis And Related Disorders中国学者发文选摘

1、Safety of inactivated COVID-19 vaccines in autoimmune encephalitis: A real-world cross-sectional survey
Author: Liu, Xu; Guo, Kundian; Lu, Lu; Luo, Rong; Liu, Jie; Zhou, Dong; Hong, Zhen

Journal: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2023; Vol. 70, Issue , pp. -. DOI: 10.1016/j.msard.2022.104495
2、Significant retinal microvascular impairments in multiple sclerosis assessed through optical coherence tomography angiography
Author: Wang, Xuejiao; Wang, Xuqian; Chou, Yuyu; Ma, Jin; Zhong, Yong

Journal: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2023; Vol. 70, Issue , pp. -. DOI: 10.1016/j.msard.2023.104505
3、Secreted aminoacyl-tRNA synthetase-interacting multifunctional protein-1 (AIMP1) is a promising predictor for the severity of acute AQP4-IgG positive neuromyelitis optica spectrum disorder
Author: Yuan, Congcong; Liu, Xueyu; Cai, Shuang; Zhang, Lu; Guo, Ruoyi; Jia, Zhen; Sun, Yafei; Li, Bin

Journal: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2023; Vol. 70, Issue , pp. -. DOI: 10.1016/j.msard.2023.104504
4、Differentiation of MOGAD in ADEM-like presentation children based on FLAIR MRI features
Author: Wei, Shaonong; Xu, Lu; Zhou, Deyang; Wang, Tianlei; Liu, Kezhou; Gao, Feng; Cao, Jiuwen

Journal: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2023; Vol. 70, Issue , pp. -. DOI: 10.1016/j.msard.2022.104496
5、Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study
Author: Zhao, Daidi; Zhao, Cong; Lu, Jiarui; Han, Yu; Sun, Tangna; Ren, Kaixi; Ma, Chao; Zhang, Chao; Li, Hongzeng; Guo, Jun

Journal: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2023; Vol. 70, Issue , pp. -. DOI: 10.1016/j.msard.2023.104518
6、B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: A real-world case series study
Author: Cao, Shugang; Wang, Xiaoyuan; Ji, Xiaopei; Tian, Jingluan; Zhu, Yunfei; Wang, Xin; Gu, Yanzheng; Duan, Xiaoyu; Xiao, Xinyi; Fang, Qi; Zhang, Xueguang; Xue, Qun

Journal: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2023; Vol. 70, Issue , pp. -. DOI: 10.1016/j.msard.2023.104524
7、Clinical characteristics of late-onset neuromyelitis optica spectrum disorder
Author: Min, Wanwan; Zhang, Li; Wang, Shengnan; Xue, Mengru; Guo, Chunjie; Zhu, Mingqin

Journal: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2023; Vol. 70, Issue , pp. -. DOI: 10.1016/j.msard.2023.104517
8、Microstructural alterations in different types of lesions and their perilesional white matter in relapsing-remitting multiple sclerosis based on diffusion kurtosis imaging
Author: Shi, Zhuowei; Pan, Yang; Yan, Zichun; Ding, Shuang; Hu, Hai; Wei, Yiqiu; Luo, Dan; Xu, Yuhui; Zhu, Qiyuan; Li, Yongmei

Journal: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2023; Vol. 71, Issue , pp. -. DOI: 10.1016/j.msard.2023.104572